Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · IEX Real-Time Price · USD

0.677

+0.004 (0.64%)

At close: Apr 19, 2024, 3:16 PM

0.710

+0.033 (4.84%)

After-hours: Apr 19, 2024, 5:14 PM EDT

Virax Biolabs Group Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019
Revenue	0.01	0	0.12	0.1
Revenue Growth (YoY)	-	-	23.97%	-
Cost of Revenue	0.01	0	0.13	0.05
Gross Profit	-0	0	-0.01	0.05
Selling, General & Admin	5.33	1.3	0.51	0.61
Research & Development	0.4	0.43	0.12	0.09
Operating Expenses	5.73	1.73	0.64	0.7
Operating Income	-5.73	-1.73	-0.64	-0.65
Interest Expense / Income	0.02	0.02	0.03	0.09
Other Expense / Income	-0.29	-0.04	-0.02	-0.03
Pretax Income	-5.46	-1.71	-0.65	-0.71
Net Income	-5.46	-1.71	-0.65	-0.71
Shares Outstanding (Basic)	1	1	0	0
Shares Outstanding (Diluted)	1	1	0	0
Shares Change	11.15%	297.67%	130.43%	-
EPS (Basic)	-5.10	-1.80	-4.10	-11.40
EPS (Diluted)	-5.10	-1.80	-4.10	-11.40
Free Cash Flow	-4.36	-0.81	-0.59	-0.74
Free Cash Flow Per Share	-4.10	-0.85	-2.45	-7.13
Gross Margin	-15.94%	-	-7.62%	45.81%
Operating Margin	-66963.68%	-	-520.54%	-652.05%
Profit Margin	-63748.32%	-	-525.75%	-711.32%
Free Cash Flow Margin	-50907.25%	-	-476.65%	-745.54%
EBITDA	-5.44	-1.69	-0.62	-0.62
EBITDA Margin	-63567.64%	-	-502.62%	-620.52%
EBIT	-5.44	-1.69	-0.62	-0.62
EBIT Margin	-63567.64%	-	-502.62%	-620.52%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).